YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Complete Genomics Rejects Counter Bid


November 14, 2012 | Complete Genomics received an unsolicited counter bid on November 5 that could have disrupted the firm's ongoing acquisition by BGI. The bid, from "Party H", was for $3.30 per share, 5% more than the BGI offer price, however Complete Genomics rejected the offer on November 8. After reviewing the proposal, the Complete board decided that the new offer did not constitute a "superior proposal" because it would likely not receive antitrust clearance. Street Insider 

View Next Related Story
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.